Rallybio Corporation (NASDAQ:RLYB) Given Consensus Rating of “Reduce” by Analysts

Shares of Rallybio Corporation (NASDAQ:RLYB) have received a consensus rating of “Reduce” from the five analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $5.00.

A number of brokerages have recently commented on RLYB. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Wall Street Zen lowered shares of Rallybio from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th.

Hedge Funds Weigh In On Rallybio

An institutional investor recently raised its position in Rallybio stock. Citadel Advisors LLC lifted its position in Rallybio Corporation (NASDAQ:RLYB) by 576.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 438,705 shares of the company’s stock after purchasing an additional 373,821 shares during the period. Citadel Advisors LLC owned about 1.04% of Rallybio worth $219,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Trading Down 3.8%

Shares of RLYB opened at $0.71 on Friday. Rallybio has a 12-month low of $0.22 and a 12-month high of $1.03. The company has a market cap of $29.99 million, a PE ratio of -2.22 and a beta of -1.05. The stock has a 50-day moving average price of $0.69 and a 200-day moving average price of $0.58.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.07 million. Rallybio had a negative net margin of 2,102.37% and a negative return on equity of 65.23%. As a group, analysts predict that Rallybio will post -1.34 earnings per share for the current year.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.